Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors
出版年份 2016 全文链接
标题
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors
作者
关键词
Human Immunodeficiency Virus, Tenofovir Disoproxil Fumarate, Severe Renal Impairment, Raltegravir, Moderate Hepatic Impairment
出版物
CLINICAL PHARMACOKINETICS
Volume 56, Issue 1, Pages 25-40
出版商
Springer Nature
发表日期
2016-06-18
DOI
10.1007/s40262-016-0424-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- First reported use of elvitegravir and cobicistat during pregnancy
- (2016) Stein Schalkwijk et al. AIDS
- Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment
- (2016) Anton Pozniak et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
- (2015) Jianping Zhang et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
- (2015) Maren I. Blonk et al. CLINICAL INFECTIOUS DISEASES
- Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients
- (2015) Leonardo Calza et al. Infectious Diseases
- Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
- (2014) J. M. Custodio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Editorial Commentary: Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs
- (2014) C. V. Fletcher CLINICAL INFECTIOUS DISEASES
- Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study
- (2014) Caroline Barau et al. CLINICAL INFECTIOUS DISEASES
- Protecting the Fetus Against HIV Infection: A Systematic Review of Placental Transfer of Antiretrovirals
- (2014) Shelley A. McCormack et al. CLINICAL PHARMACOKINETICS
- Raltegravir Pharmacokinetics During Pregnancy
- (2014) D. Heather Watts et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food
- (2014) Stephen Weller et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study
- (2014) Mari Shiomi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
- (2014) Beatriz Grinsztejn et al. LANCET INFECTIOUS DISEASES
- Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
- (2013) Stephen Castellino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Binding of Raltegravir to Plasma Proteins
- (2013) Caroline Barau et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacological considerations on the use of antiretrovirals in pregnancy
- (2013) Angela Colbers et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
- (2013) Stephen Weller et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)
- (2013) B. Hernandez-Novoa et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals
- (2012) Mona Arab-Alameddine et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients
- (2012) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
- (2012) Marco Siccardi et al. THERAPEUTIC DRUG MONITORING
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
- (2011) Ivy Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers
- (2011) P. Patel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease
- (2010) J. Molto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers
- (2010) J. J. Kiser et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Drug Interactions Should Be Evaluated in Patients
- (2010) C V Fletcher CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV
- (2010) Polina German et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics
- (2010) Diana M. Brainard et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
- (2010) Andrew R. Zolopa et al. JOURNAL OF INFECTIOUS DISEASES
- Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis
- (2009) Pierre Giguère et al. AIDS
- Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis
- (2009) David M Burger et al. AIDS
- Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
- (2009) M. Iwamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms
- (2009) LA Wenning et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination
- (2007) H. Jeong et al. XENOBIOTICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started